Infectious Disease Doctors in Oklahoma Medicare Details, Address, Contact
46 Infectious Disease doctors found. Showing 41 - 46
 Sristi Bhattarai, M.D Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 10507 E 91st St Ste 110, Tulsa, OK 74133 Phone: 918-307-3100 Fax: 918-307-3101 |
 Zoheir Khan, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1145 S Utica Ave Ste G12, Tulsa, OK 74104 Phone: 918-579-5788 Fax: 918-579-5017 |
Edemekong Bassey, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 6161 S Yale Ave, Tulsa, OK 74136 Phone: 918-502-4254 Fax: 918-502-2265 |
Dr. Heather Linette Bell, DO Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1919 S Wheeling Ave Ste 606, Tulsa, OK 74104 Phone: 918-748-7665 |
Kelley M Struble, DO Internal Medicine - Infectious Disease Medicare: Medicare Enrolled Practice Location: 1919 S Wheeling Ave Ste 606, Tulsa, OK 74104 Phone: 918-748-7665 |
Dr. Mark Henry Grosserode, MD Internal Medicine - Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 6565 S Yale Ave, Ste 812, Tusla, OK 74136 Phone: 918-494-9486 Fax: 918-494-9480 |
News Archive
IPEMA compiles list of 5 important steps to help ensure safety of children on playground
With the recent announcement of First Lady Michelle Obama's Let's Move initiative to battle childhood obesity, The International Play Equipment Manufacturers Association is reminding parents and caregivers of the importance of providing an hour of free play outdoors in a safe play environment during National Playground Safety Week (April 26-30).
Osteoporosis drug Raloxifene shown to be as effective as Tamoxifen in preventing invasive breast cancer
Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.
FDA approves Schering-Plough's New Drug Application for ZEGERID OTC capsules
Santarus, Inc., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Schering-Plough HealthCare Products, Inc.'s, New Drug Application (NDA) for ZEGERID OTC™ Capsules (omeprazole/sodium bicarbonate) with a dosage strength of 20 mg of omeprazole for over-the-counter (OTC) treatment of frequent heartburn.
Abnormalities observed in cloned mice help reinforce the need to continue to avoid the reproductive cloning of humans
Dr. Takumi Takeuchi, from Cornell University, New York, USA told a media briefing that he and Dr. Gianpiero Palermo's team had compared imprinting abnormalities (the process where specific genes inherited from both parents are silent) in mice embryos derived from assisted reproduction techniques and from cloning.
› Verified 8 days ago